E Jason Abel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4005966/publications.pdf

Version: 2024-02-01

97 papers	2,353 citations	236925 25 h-index	223800 46 g-index
99 all docs	99 docs citations	99 times ranked	2899 citing authors

#	Article	IF	Citations
1	Natural history of simple renal cysts: longitudinal CT-based evaluation. Abdominal Radiology, 2022, 47, 1124-1132.	2.1	3
2	Split-bolus CT urography after microwave ablation of renal cell carcinoma improves image quality and reduces radiation exposure. Abdominal Radiology, 2022, , 1.	2.1	0
3	Contrast-enhanced CT immediately following percutaneous microwave ablation of cT1a renal cell carcinoma: Optimizing cancer outcomes. Abdominal Radiology, 2022, 47, 2674-2680.	2.1	3
4	Models of Renal Cell Carcinoma Used to Investigate Molecular Mechanisms and Develop New Therapeutics. Frontiers in Oncology, 2022, 12, 871252.	2.8	8
5	Summary from the Kidney Cancer Associationâ€™s Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer, 2021, 19, 167-175.	1.9	4
6	Evaluation of radiomics and machine learning in identification of aggressive tumor features in renal cell carcinoma (RCC). Abdominal Radiology, 2021, 46, 4278-4288.	2.1	8
7	Editorial Comment. Journal of Urology, 2021, 205, 1319-1319.	0.4	2
8	Comparison of CT Texture Analysis Software Platforms in Renal Cell Carcinoma: Reproducibility of Numerical Values and Association With Histologic Subtype Across Platforms. American Journal of Roentgenology, 2021, 216, 1549-1557.	2.2	4
9	Evolution of risk stratification systems is critical for improving patient selection for cytoreductive nephrectomy. Cancer, 2021, 127, 3920-3923.	4.1	2
10	Microwave Ablation of Renal Cell Carcinoma. Journal of Endourology, 2021, 35, S-33-S-37.	2.1	4
11	Beta-Adrenergic Antagonists and Cancer Specific Survival in Patients With Advanced Prostate Cancer: A Veterans Administration Cohort Study. Urology, 2021, 155, 186-191.	1.0	4
12	Combining Stereotactic Body Radiotherapy and Microwave Ablation Appears Safe and Feasible for Renal Cell Carcinoma in an Early Series. Clinical Genitourinary Cancer, 2021, 19, e313-e318.	1.9	4
13	Effect of iodinated contrast material on post-operative eGFR when administered during renal mass ablation. European Radiology, 2021, 31, 5490-5497.	4.5	5
14	Epigenetic field alterations in non-tumor prostate tissues detect prostate cancer in urine.. American Journal of Clinical and Experimental Urology, 2021, 9, 479-488.	0.4	0
15	The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. European Urology Focus, 2020, 6, 104-111.	3.1	18
16	Functional penile replantation after traumatic avulsion amputation below the pubis: A case report. Microsurgery, 2020, 40, 70-73.	1.3	3
17	CT and MR imaging surveillance of stage 1 renal cell carcinoma after microwave ablation. Abdominal Radiology, 2020, 45, 2810-2824.	2.1	5
18	Patterns of Initial Metastatic Recurrence After Surgery for High-Risk Nonmetastatic Renal Cell Carcinoma. Urology, 2020, 146, 152-157.	1.0	1

#	Article	IF	Citations
19	Microwave Ablation of Adrenal Tumors in Patients With Continuous Intra-Arterial Blood Pressure Monitoring Without Prior Alpha-Adrenergic Blockade: Safety and Efficacy. CardioVascular and Interventional Radiology, 2020, 43, 1384-1391.	2.0	4
20	Renal cell carcinoma with isolated lymph node metastases should be reclassified as stage IV. Cancer, 2020, 126, 2965-2967.	4.1	3
21	Preoperative metastatic disease burden to predict overall survival following cytoreductive nephrectomy independent of IMDC risk category.. Journal of Clinical Oncology, 2020, 38, 652-652.	1.6	1
22	Editorial Comment. Journal of Urology, 2020, 203, 503-503.	0.4	0
23	Expectations for overall survival in mRCC patients who were selected for upfront cytoreductive nephrectomy in the targeted therapy era.. Journal of Clinical Oncology, 2020, 38, 646-646.	1.6	1
24	Trends in epidural anesthesia use at the time of radical cystectomy and its association with perioperative and survival outcomes: a population-based analysis. American Journal of Clinical and Experimental Urology, 2020, 8, 28-37.	0.4	0
25	Texture analysis of small renal cell carcinomas at MDCT for predicting relevant histologic and protein biomarkers. Abdominal Radiology, 2019, 44, 1999-2008.	2.1	23
26	Utility of CT Texture Analysis in Differentiating Low-Attenuation Renal Cell Carcinoma From Cysts: A Bi-Institutional Retrospective Study. American Journal of Roentgenology, 2019, 213, 1259-1266.	2.2	19
27	Contrast-Enhanced Ultrasound in Renal Imaging and Intervention. Current Urology Reports, 2019, 20, 73.	2.2	16
28	Development of a Risk-stratified Approach for Follow-up Imaging After Percutaneous Thermal Ablation of Sporadic Stage One Renal Cell Carcinoma. Urology, 2019, 134, 148-153.	1.0	7
29	Robotically-Assisted Sonic Therapy for Renal Ablation in a Live Porcine Model: Initial Preclinical Results. Journal of Vascular and Interventional Radiology, 2019, 30, 1293-1302.	0.5	24
30	Collagen organization of renal cell carcinoma differs between low and high grade tumors. BMC Cancer, 2019, 19, 490.	2.6	41
31	Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. BMC Urology, 2019, 19, 26.	1.4	2
32	Tumor location does not impact oncologic outcomes for percutaneous microwave ablation of clinical T1a renal cell carcinoma. European Radiology, 2019, 29, 6319-6329.	4.5	23
33	Patient-specific organotypic blood vessels as an in vitro model for anti-angiogenic drug response testing in renal cell carcinoma. EBioMedicine, 2019, 42, 408-419.	6.1	33
34	Comparing oncologic outcomes in patients undergoing surgery for oncocytic neoplasms, conventional oncocytoma, and chromophobe renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 811.e17-811.e21.	1.6	4
35	Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors. Current Opinion in Urology, 2019, 29, 513-520.	1.8	9
36	The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 130-137.	1.6	27

#	Article	IF	Citations
37	Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology, 2019, 75, 111-128.	1.9	138
38	The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. Journal of Urology, 2019, 201, 742-750.	0.4	4
39	Risk Factors for Complications and Nondiagnostic Results following 1,155 Consecutive Percutaneous Core Renal Mass Biopsies. Journal of Urology, 2019, 201, 1080-1087.	0.4	19
40	Pre-surgical Treatment of Renal Cell Carcinoma. , 2019, , 247-262.		0
41	Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdominal Radiology, 2018, 43, 2446-2454.	2.1	9
42	Editorial Comment. Journal of Urology, 2018, 199, 639-639.	0.4	0
43	Comparative Analysis of Surgery, Thermal Ablation, and Active Surveillance for Renal Oncocytic Neoplasms. Urology, 2018, 112, 92-97.	1.0	17
44	Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 88.e19-88.e25.	1.6	5
45	Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. Clinical Genitourinary Cancer, 2018, 16, e443-e450.	1.9	6
46	Editorial Comment. Journal of Urology, 2018, 200, 526-527.	0.4	0
47	Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. Journal of Urology, 2018, 200, 1256-1263.	0.4	42
48	Effectiveness of a transrectal prostate needle biopsy protocol with risk-tailored antimicrobials in a veterans cohort. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 363.e13-363.e20.	1.6	1
49	Predicting aggressive behavior in small renal tumors prior to treatment. Annals of Translational Medicine, 2018, 6, S132-S132.	1.7	8
50	Effect of Tumor Complexity and Technique on Efficacy and Complications after Percutaneous Microwave Ablation of Stage T1a Renal Cell Carcinoma: A Single-Center, Retrospective Study. Radiology, 2017, 284, 272-280.	7.3	67
51	Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus. Journal of Urology, 2017, 198, 281-288.	0.4	47
52	Renal mass biopsy and thermal ablation: should biopsy be performed before or during the ablation procedure?. Abdominal Radiology, 2017, 42, 1773-1780.	2.1	29
53	Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. Journal of Urology, 2017, 198, 810-816.	0.4	26
54	Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m²) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU International, 2017, 120, 387-393.	2.5	8

#	Article	IF	Citations
55	Percutaneous biopsy in large, locally advanced or metastatic renal tumors. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 87-91.	1.6	9
56	Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. Current Urology Reports, 2017, 18, 48.	2.2	2
57	Surgical Treatment of 4â€“10â€‰cm Renal-Cell Carcinoma: A Survey of the Lions and Gazelles. Journal of Endourology, 2017, 31, S-43-S-47.	2.1	2
58	Editorial Comment. Journal of Urology, 2017, 198, 295-295.	0.4	0
59	Editorial Comment. Urology, 2017, 108, 121.	1.0	0
60	Editorial Comment. Journal of Urology, 2017, 198, 537-537.	0.4	0
61	Metastatic Tumor Burden Does Not Predict Overall Survival Following Cytoreductive Nephrectomy for Renal Cell Carcinoma: a Novel 3-Dimensional Volumetric Analysis. Urology, 2017, 100, 139-144.	1.0	5
62	Extreme obesity does not predict poor cancer outcomes after surgery for renal cell cancer. BJU International, 2016, 118, 399-407.	2.5	5
63	Re: Lorenzo Marconi, Saeed Dabestani, Thomas B. Lam, et al. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol 2016;69:660â€“73. European Urology, 2016, 69, e117-e118.	1.9	3
64	Percutaneous biopsy facilitates modern treatment of renal masses. Abdominal Radiology, 2016, 41, 617-619.	2.1	8
65	Neovascularity as a prognostic marker in renal cell carcinoma. Human Pathology, 2016, 57, 98-105.	2.0	18
66	Risk factors for recurrence after surgery in nonâ€metastatic <scp>RCC</scp> with thrombus: a contemporary multicentre analysis. BJU International, 2016, 117, E87-94.	2.5	39
67	A Critical Analysis of Perioperative Outcomes in Morbidly Obese Patients Following Renal Mass Surgery. Urology, 2016, 96, 93-98.	1.0	3
68	Editorial Comment. Urology, 2016, 96, 113.	1.0	0
69	Surveillance following surgery for nonmetastatic renal cell carcinoma. Current Opinion in Urology, 2016, 26, 432-438.	1.8	6
70	CT Textural Analysis of Large Primary Renal Cell Carcinomas: Pretreatment Tumor Heterogeneity Correlates With Histologic Findings and Clinical Outcomes. American Journal of Roentgenology, 2016, 207, 96-105.	2.2	117
71	Variability of interâ€observer agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (<scp>RCC</scp>): independent analysis from a phase <scp>II</scp> trial. BJU International, 2016, 117, 629-635.	2.5	18
72	Percutaneous Microwave Ablation of Renal Angiomyolipomas. CardioVascular and Interventional Radiology, 2016, 39, 433-440.	2.0	16

#	Article	IF	Citations
73	The evolving role of renal mass biopsy. Annals of Translational Medicine, 2016, 4, 83.	1.7	1
74	Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2015, 194, 1214-1219.	0.4	16
75	Addressing the need for repeat prostate biopsy: new technology and approaches. Nature Reviews Urology, 2015, 12, 435-444.	3.8	22
76	Multi-Quadrant Biopsy Technique Improves Diagnostic Ability in Large Heterogeneous Renal Masses. Journal of Urology, 2015, 194, 886-891.	0.4	41
77	Patient and Tumor Characteristics can Predict Nondiagnostic Renal Mass Biopsy Findings. Journal of Urology, 2015, 193, 1899-1904.	0.4	75
78	Highest risk of symptomatic venous thromboembolic events after radical cystectomy occurs in patients with obesity or nonurothelial cancers. Urology Annals, 2015, 7, 355.	0.6	10
79	Positive vascular wall margins have minimal impact on cancer outcomes in patients with nonâ€metastatic renal cell carcinoma (<scp>RCC</scp>) with tumour thrombus. BJU International, 2014, 114, 667-673.	2.5	29
80	Perioperative Blood Transfusion and Radical Cystectomy: Does Timing of Transfusion Affect Bladder Cancer Mortality?. European Urology, 2014, 66, 1139-1147.	1.9	67
81	Perioperative Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Cava Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Experience. European Urology, 2014, 66, 584-592.	1.9	100
82	Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expression. Human Pathology, 2014, 45, 1092-1099.	2.0	58
83	Oncologic Outcomes Following Surgical Resection of Renal Cell Carcinoma with Inferior Vena Caval Thrombus Extending Above the Hepatic Veins: A Contemporary Multicenter Cohort. Journal of Urology, 2014, 192, 1050-1056.	0.4	76
84	Surgical Operative Time Increases the Risk of Deep Venous Thrombosis and Pulmonary Embolism in Robotic Prostatectomy. Journal of the Society of Laparoendoscopic Surgeons, 2014, 18, 282-287.	1.1	22
85	Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. European Urology, 2013, 63, 947-952.	1.9	67
86	Preoperative Pulmonary Embolism Does Not Predict Poor Postoperative Outcomes in Patients with Renal Cell Carcinoma and Venous Thrombus. Journal of Urology, 2013, 190, 452-457.	0.4	25
87	Ablation of Small Renal Masses: Practice Patterns at Academic Institutions in the United States. Journal of Endourology, 2013, 27, 158-161.	2.1	32
88	Delayed Ureterectomy after Incomplete Nephroureterectomy for Upper Tract Urothelial Carcinoma: Pathologic Findings and Outcomes. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2013, 39, 817-822.	1.5	3
89	Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU International, 2012, 110, 1742-1746.	2.5	55
90	Laparoscopic Adrenalectomy for Metachronous Metastases After Ipsilateral Nephrectomy for Renal-Cell Carcinoma. Journal of Endourology, 2011, 25, 1323-1327.	2.1	13

#	Article	IF	Citations
91	Early Primary Tumor Size Reduction Is an Independent Predictor of Improved Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib. European Urology, 2011, 60, 1273-1279.	1.9	69
92	Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2011, 59, 10-15.	1.9	98
93	The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor Thrombus. European Urology, 2011, 59, 912-918.	1.9	167
94	Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. Cancer, 2010, 116, 3378-3388.	4.1	183
95	Identifying the risk of disease progression after surgery for localized renal cell carcinoma. BJU International, 2010, 106, 1277-1283.	2.5	20
96	Percutaneous Biopsy of Primary Tumor in Metastatic Renal Cell Carcinoma to Predict High Risk Pathological Features: Comparison With Nephrectomy Assessment. Journal of Urology, 2010, 184, 1877-1881.	0.4	67
97	Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nature Reviews Urology, 2009, 6, 375-383.	3.8	44